Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darbepoetin alfa biosimilar
- Development stage
- Phase 1
- Lead developer
- HK inno.N Corporation
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
CJ-40001 is a biosimilar of darbepoetin alfa developed for the treatment of renal anaemia, particularly anaemia caused by chronic kidney disease or cancer chemotherapy. It acts as an erythropoiesis stimulant and functions as an agonist at the erythropoietin receptor. The drug is designed to offer reduced administration frequency compared to first-generation treatments—typically once per week or once every two weeks. Developed originally by CJ HealthCare (now HK inno.N), it has been licensed for development and commercialization in China by NCPC GeneTech Biotechnology, a subsidiary of North China Pharmaceutical Company. Clinical studies have demonstrated that CJ-40001 has comparable pharmacokinetic, pharmacodynamic, and safety profiles to reference darbepoetin alfa (NESP), supporting its use as an interchangeable alternative[1][3][4][5].
- Other names
- darbepoetin alfa biosimilarCJ-40001CJ40001CJ 40001YLB217YLB-217YLB 217
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on darbepoetin alfa biosimilar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darbepoetin alfa biosimilar.